drugset
drugset / Trial / NCT06999902

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

NCT06999902 ↗

Phase 2/3 Recruiting 230 enrolled Praxis Precision Medicines
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)

Timeline

Start
2024-12-11
Primary completion
2025-11-24
Completion
2025-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject PRAX-628 Unknown 30 mg Oral

Indications

focal epilepsy